Log In
BCIQ
Print this Print this
 

Dexilant, dexlansoprazole (TAK-390MR)

Also known as: formerly Kapidex, Kapidex

  Manage Alerts
Collapse Summary General Information
Company Takeda Pharmaceutical Co. Ltd.
DescriptionOral proton pump inhibitor (PPI)
Molecular Target H+/K ATPase pump
Mechanism of ActionH+/K+ ATPase pump inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationGastroesophageal reflux disease (GERD)
Indication DetailsTreat erosive esophagitis (EE); Treat erosive esophagitis (EE), maintain the healing of erosive esophagitis and treat symptomatic non-erosive gastroesophageal reflux disease (GERD); Treat gastroesophageal reflux disease (GERD); Treat heartburn and other symptoms associated with gastroesophageal reflux disease (GERD); Treat non-erosive gastroesophageal reflux disease (GERD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/27/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today